Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating on July 22.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Risinger has given his Buy rating due to a combination of factors that highlight Sanofi’s strategic moves to enhance its vaccine portfolio. The acquisition of Vicebio, a company specializing in respiratory disease prevention, for $1.15 billion upfront, represents a strategic expansion of Sanofi’s non-mRNA vaccine pipeline. This acquisition is expected to bolster Sanofi’s capabilities in vaccine design and development, particularly with the addition of Vicebio’s ‘Molecular Clamp’ technology, which facilitates the quicker development of fully liquid combination vaccines.
Furthermore, the acquisition aligns with Sanofi’s ongoing commitment to developing protein-based combination vaccines, as evidenced by its previous partnership with NVAX for COVID-19/Flu combinations. This transaction not only strengthens Sanofi’s position in the vaccine market but also reflects a broader trend of increased M&A activity in the large-cap biopharma sector. Risinger views these strategic moves as positive indicators for Sanofi’s future growth and operational efficiency, reinforcing his Buy rating on the stock.
In another report released on July 22, Bernstein also reiterated a Buy rating on the stock with a €124.00 price target.